Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Multi-component Intervention for Diabetes in Adults With Serious Mental Illness (MIDAS)

15 de setembro de 2021 atualizado por: Dilip V. Jeste, University of California, San Diego

Multi-component Intervention for Diabetes in Adults With Serious Mental Illness (MIDAS)

Persons with schizophrenia and other serious mental illnesses have a high risk for type 2 diabetes and an increased risk of premature mortality compared to the general population. The goals of the proposed study are to implement a multimodal lifestyle intervention to reduce that risk in these individuals living in residential care facilities, a common housing modality for people with serious mental illnesses. If successful, this intervention will lead to reduction in excess medical comorbidity and mortality in persons with serious mental illnesses.

Visão geral do estudo

Descrição detalhada

Serious mental illnesses (SMI), including schizophrenia, bipolar disorder, and schizoaffective disorder, are associated with increased medical comorbidity and premature mortality from diabetes and cardiovascular disease. Unhealthy lifestyles, including energy-dense (obesogenic) diet, sedentary behavior, and cigarette smoking are important risk factors for diabetes and accelerated biological aging. All of these risk factors are potentially modifiable. There is considerable literature documenting the effectiveness of strategies to prevent and manage diabetes in the general population; yet, these interventions are rarely offered to people with SMI. Residential Care Facilities (RCFs), called Board-and-Care Homes in California, are a common housing modality for patients with SMI; they provide a venue that can maximize efficiency and sustainability of a lifestyle intervention. The goals of the proposed four-year study are to tailor a multi-component intervention to this high-risk group. The study will be a hybrid effectiveness-implementation (Hybrid Type 1) trial of a Multi-component Intervention for Diabetes risk reduction in Adults with SMI (MIDAS) in licensed RCFs in San Diego county. As a Hybrid Type 1 study, the primary emphasis will be on determining the effectiveness of the intervention to achieve desired health outcomes while also systematically collecting data on its implementation within RCFs that will inform implementation strategy refinement. Main components of MIDAS include: (1) Education about diabetes and lifestyle, (2) Dietary intervention at the facility and resident level, (3) Increased physical activity, and (4) Smoking cessation / reduction. The investigators will employ a modified cluster-randomized stepped wedge and adaptive trial design involving 210 residents with SMI and 120 staff members from 12 RCFs. The RCFs will be divided randomly into four cohorts of three RCFs each. Each cohort will be tested over a 15-month period that includes three phases: a three-month initial control phase (no intervention, from baseline month 0 to end of month 3), a six-month intervention phase (months 4 through 9), and a six-month follow-up phase (no intervention, months 10 through 15). All the study participants will be assessed quarterly during the 15-month period. Our investigators will train RCF staff (especially the Activity Director and cook) to increase physical activity and reduce smoking, and to implement healthful dietary modifications among the residents, using evidence-based interventions. During the intervention phase, the RCF Activity Director will conduct twice-weekly manualized group sessions on education about diabetes, nutrition, exercise, and smoking cessation/reduction, to deliver a multi-component group intervention. We will also explore if there are improvements in blood-based research biomarkers of insulin resistance and inflammation in the RCF residents with SMI. This project is responsive to RFA-MH-17-608, and related to NIMH Strategic Objective #3.3B: testing interventions for effectiveness in community practice settings. If successful, MIDAS will be sustained and disseminated, and would lead to reduction in excess medical comorbidity and mortality associated with SMI.

Tipo de estudo

Intervencional

Inscrição (Antecipado)

210

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Dilip V Jeste, MD
  • Número de telefone: (858) 534-4020
  • E-mail: djeste@ucsd.edu

Estude backup de contato

  • Nome: Danielle K Glorioso, LCSW
  • Número de telefone: (858) 246-0767
  • E-mail: dglorioso@ucsd.edu

Locais de estudo

    • California
      • La Jolla, California, Estados Unidos, 92093
        • Recrutamento
        • University of California, San Diego Division of Geriatric Psychiatry
        • Contato:
        • Contato:
        • Investigador principal:
          • Dilip V Jeste, MD

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 65 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Participants: A total of 12 RCFs (30 to 45 beds each), 210 resident participants, and 120 staff members (1 manager, 2 activity directors, 1 cook, and 6 other staff members per facility) will be enrolled.

Inclusion and Exclusion Criteria:

Residential Care Facilities (RCFs):

Inclusion Criteria:

  1. Licensed by California Division of Social Services' Community Care Licensing
  2. Serves only individuals with SMI
  3. Has >15 residents currently living in the facility
  4. Willing to participate

Staff Participants:

Inclusion Criteria:

  1. Age >21 years
  2. Fluent in English
  3. Written informed consent to participate

Exclusion Criteria:

(1) Plans to leave the RCF during the next year.

Resident Participants:

Inclusion Criteria:

  1. Age 18 - 65 years
  2. Chart diagnosis of an SMI, mainly schizophrenia, schizoaffective disorder, or bipolar disorder
  3. Current treatment with antipsychotics
  4. Fluent in English
  5. Written informed consent to participate in this study

Exclusion Criteria:

  1. Chart diagnosis of dementia or intellectual disability disorder
  2. Active substance abuse (non-tobacco)
  3. Medical problems that interfere with ability to complete assessments and intervention

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Prevenção
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição sequencial
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Sem intervenção: Control Phase
3-month initial control phase (no intervention, month 1-3)
Experimental: Intervention Phase
6-month intervention phase - MIDAS Intervention Delivered. Followed by 6-month follow-up phase (no intervention, months 10-15).
Main components of MIDAS include: (1) Education about diabetes and lifestyle, (2) Dietary intervention at the facility and resident level, (3) Increased physical activity, and (4) Smoking cessation / reduction.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Body Mass Index (BMI in kg/m^2)
Prazo: Baseline to 9 months and sustained at 15 months
Change in Body Mass Index
Baseline to 9 months and sustained at 15 months
Waist Circumference
Prazo: Baseline to 9 months and sustained at 15 months
Change in Waist Circumference
Baseline to 9 months and sustained at 15 months
Fasting Glucose
Prazo: Baseline to 9 months and sustained at 15 months
Change in Fasting Glucose
Baseline to 9 months and sustained at 15 months
Hemoglobin A1c or HbA1c
Prazo: Baseline to 9 months and sustained at 15 months
Change in Hemoglobin A1c or HbA1c
Baseline to 9 months and sustained at 15 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Diet/Nutrition - Plasma Carotenoid Levels
Prazo: Baseline to 9 months and sustained at 15 months
Plasma Carotenoid levels reflect changing dietary vegetable and fruit intake.Nutrition Data Systems for REsearch (NDS-R) Protocol
Baseline to 9 months and sustained at 15 months
Diet/Nutrition - Serum Lipid Levels
Prazo: Baseline to 9 months and sustained at 15 months
Plasma Carotenoid levels reflect changing dietary vegetable and fruit intake.
Baseline to 9 months and sustained at 15 months
Objective Measure of Physical Activity
Prazo: Baseline to 9 months and sustained at 15 months
For 7 days during each assessment period, participants will wear the GT3X+ Actigraph, which measures movement and intensity of activity, and has good validation with VO2max. It provides estimates of activity by seconds, that can be categorized into minutes spent in sedentary, light, moderate, and vigorous activity using calibration thresholds.
Baseline to 9 months and sustained at 15 months
Smoking - Expired Breath Carbon Monoxide (CO) Levels
Prazo: Baseline to 9 months and sustained at 15 months
Change in Smoking - Objective Measure of Cigarette Use: Expired Breath Carbon Monoxide (CO) level (parts per million) is measured with a handheld device. CO monitoring is used primarily as a check on recent smoking, though it has also been used to indicate reductions in smoking.
Baseline to 9 months and sustained at 15 months
Smoking - Change in Smoking through Recall
Prazo: Baseline to 9 months and sustained at 15 months
Change in Smoking - Quantity and frequency of cigarette use for the prior week using a timeline followback procedure. Smoking reduction calculated by % change in average cigarettes/day across assessments.
Baseline to 9 months and sustained at 15 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

28 de dezembro de 2018

Conclusão Primária (Antecipado)

31 de maio de 2022

Conclusão do estudo (Antecipado)

31 de maio de 2022

Datas de inscrição no estudo

Enviado pela primeira vez

5 de julho de 2018

Enviado pela primeira vez que atendeu aos critérios de CQ

9 de agosto de 2018

Primeira postagem (Real)

13 de agosto de 2018

Atualizações de registro de estudo

Última Atualização Postada (Real)

17 de setembro de 2021

Última atualização enviada que atendeu aos critérios de controle de qualidade

15 de setembro de 2021

Última verificação

1 de setembro de 2021

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever